X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3167) 3167
Book Chapter (15) 15
Newsletter (13) 13
Magazine Article (12) 12
Newspaper Article (6) 6
Conference Proceeding (3) 3
Book Review (1) 1
Dissertation (1) 1
Government Document (1) 1
Transcript (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2794) 2794
science & technology (2293) 2293
life sciences & biomedicine (2162) 2162
hiv infections - drug therapy (2052) 2052
ritonavir - therapeutic use (1924) 1924
male (1729) 1729
female (1561) 1561
adult (1418) 1418
hiv protease inhibitors - therapeutic use (1275) 1275
ritonavir (1171) 1171
infectious diseases (1094) 1094
middle aged (1073) 1073
drug therapy, combination (1035) 1035
anti-hiv agents - therapeutic use (953) 953
pharmacology & pharmacy (945) 945
ritonavir - administration & dosage (798) 798
lopinavir (793) 793
hiv (720) 720
aids/hiv (654) 654
hiv infections - virology (636) 636
ritonavir - adverse effects (631) 631
treatment outcome (595) 595
viral load (593) 593
immunology (560) 560
virology (498) 498
hiv-1 - drug effects (490) 490
protease inhibitors (490) 490
drug interactions (487) 487
antiviral agents (486) 486
hiv protease inhibitors - administration & dosage (477) 477
hiv protease inhibitors - adverse effects (472) 472
ritonavir - pharmacokinetics (454) 454
cd4 lymphocyte count (446) 446
drug therapy (433) 433
pyrimidinones - therapeutic use (406) 406
hiv infection (386) 386
human immunodeficiency virus--hiv (384) 384
microbiology (373) 373
anti-hiv agents - administration & dosage (360) 360
ritonavir - pharmacology (358) 358
reverse transcriptase inhibitors - therapeutic use (352) 352
sulfonamides - therapeutic use (345) 345
hiv protease inhibitors - pharmacokinetics (343) 343
antiretroviral therapy, highly active (341) 341
drug combinations (319) 319
aged (313) 313
rna, viral - blood (313) 313
antiretroviral therapy (312) 312
antiretroviral drugs (306) 306
anti-hiv agents - adverse effects (302) 302
hiv-1 (294) 294
darunavir (291) 291
pharmacokinetics (287) 287
pyridines - therapeutic use (285) 285
hiv-1 - genetics (283) 283
lopinavir - therapeutic use (282) 282
young adult (275) 275
health aspects (274) 274
adolescent (272) 272
atazanavir sulfate (270) 270
research (266) 266
hiv protease inhibitors - pharmacology (262) 262
hiv infections - immunology (261) 261
dosage and administration (258) 258
drug administration schedule (258) 258
saquinavir - therapeutic use (258) 258
highly active antiretroviral therapy (246) 246
hiv infections - blood (244) 244
hiv infections - complications (242) 242
antiviral agents - therapeutic use (239) 239
patients (238) 238
analysis (236) 236
indinavir - therapeutic use (232) 232
aids (231) 231
lamivudine - therapeutic use (231) 231
genotype (221) 221
care and treatment (220) 220
abridged index medicus (219) 219
prospective studies (217) 217
virus diseases (216) 216
anti-hiv agents - pharmacokinetics (205) 205
oligopeptides - therapeutic use (203) 203
retrospective studies (203) 203
tenofovir (203) 203
proteases (191) 191
clinical trials (185) 185
sulfonamides - administration & dosage (182) 182
human immunodeficiency virus (180) 180
cohort studies (179) 179
child (175) 175
pyrimidinones - administration & dosage (175) 175
viruses (175) 175
ritonavir - blood (171) 171
time factors (167) 167
drug resistance, viral (165) 165
infections (163) 163
hepatitis c (161) 161
animals (160) 160
zidovudine - therapeutic use (160) 160
area under curve (158) 158
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3108) 3108
Spanish (71) 71
French (25) 25
German (18) 18
Japanese (8) 8
Portuguese (8) 8
Chinese (5) 5
Dutch (3) 3
Russian (3) 3
Czech (2) 2
Hebrew (1) 1
Italian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet infectious diseases, ISSN 1473-3099, 07/2015, Volume 15, Issue 7, pp. 775 - 784
Journal Article
The New England journal of medicine, ISSN 1533-4406, 04/2014, Volume 370, Issue 17, pp. 1594 - 1603
Journal Article
The New England journal of medicine, ISSN 1533-4406, 04/2014, Volume 370, Issue 17, pp. 1604 - 1614
Journal Article
The Journal of infectious diseases, ISSN 1537-6613, 10/2015, Volume 212, Issue 8, pp. 1241 - 1249
Journal Article
Gastroenterology (New York, N.Y. 1943), ISSN 0016-5085, 2014, Volume 147, Issue 2, pp. 359 - 365.e1
Background & Aims The interferon-free regimen of ABT-450 (a protease inhibitor), ritonavir, ombitasvir (an NS5A inhibitor), dasabuvir (a non-nucleoside... 
Gastroenterology and Hepatology | IFN | PEARL-II | Ribavirin-Free | Interferon-Free Therapy | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Anilides - therapeutic use | Puerto Rico | Hepatitis C - drug therapy | United States | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Male | RNA, Viral - blood | Viral Load | Ritonavir - adverse effects | Time Factors | Ritonavir - therapeutic use | Adult | Female | Drug Therapy, Combination | Hepacivirus - drug effects | Antiviral Agents - therapeutic use | Europe | Ribavirin - therapeutic use | Uracil - therapeutic use | Genotype | Treatment Outcome | Macrocyclic Compounds - adverse effects | Biomarkers - blood | Macrocyclic Compounds - therapeutic use | Hepatitis C - diagnosis | Uracil - adverse effects | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Sulfonamides - adverse effects | Carbamates - adverse effects | Hepacivirus - growth & development | Aged | Carbamates - therapeutic use | Uracil - analogs & derivatives | Medical colleges | Care and treatment | Proteases | Ritonavir | Biological products industry | Genetic aspects | Biological response modifiers | Hepatitis C virus | Hepatitis C | Health aspects | Ribavirin | Index Medicus | Abridged Index Medicus
Journal Article
BMC gastroenterology, ISSN 1471-230X, 08/2015, Volume 15, Issue 1, pp. 98 - 98
Background: The standard care of treatment of interferon plus ribavirin (plus protease inhibitor for genotype 1) are effective in 50 % to 70 % of patients with... 
Chronic hepatitis C | Olysio | Viekira Pak | Harvoni | Markov model | Cost-effectiveness | Sofosbuvir | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Interferons - economics | Markov Chains | Fluorenes - economics | Ribavirin - economics | Humans | Middle Aged | Simeprevir - economics | Fluorenes - therapeutic use | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Ritonavir - economics | Male | Interferons - therapeutic use | Uridine Monophosphate - economics | Benzimidazoles - economics | Polyethylene Glycols - therapeutic use | Simeprevir - therapeutic use | Sofosbuvir - economics | Ritonavir - therapeutic use | Female | Macrocyclic Compounds - economics | Benzimidazoles - therapeutic use | Uridine Monophosphate - therapeutic use | Quality-Adjusted Life Years | Sofosbuvir - therapeutic use | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Uracil - therapeutic use | Genotype | Drug Therapy, Combination - economics | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Sulfonamides - therapeutic use | Cost-Benefit Analysis | Sulfonamides - economics | Uridine Monophosphate - analogs & derivatives | Uracil - economics | Antiviral Agents - economics | Drug Combinations | Uracil - analogs & derivatives | Economic aspects | Markov processes | Hepatitis C virus | Analysis | Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 12/2014, Volume 371, Issue 25, pp. 2375 - 2382
In this study, 34 liver-transplant recipients with recurrent HCV genotype 1 infection were treated with the interferon-free regimen of ombitasvir–ABT-450/r,... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Anilides - therapeutic use | Liver Transplantation | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Male | RNA, Viral - blood | Calcineurin Inhibitors - blood | Young Adult | Ribavirin - administration & dosage | Ritonavir - therapeutic use | Adult | Female | Drug Therapy, Combination | Hepacivirus - isolation & purification | Antiviral Agents - therapeutic use | Uracil - therapeutic use | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Sulfonamides - therapeutic use | Antiviral Agents - adverse effects | Calcineurin Inhibitors - therapeutic use | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Viral Nonstructural Proteins - antagonists & inhibitors | Uracil - analogs & derivatives | Care and treatment | Usage | Ritonavir | Liver | Dosage and administration | Transplantation | Hepatitis C | Ribavirin | Headache | Transplants & implants | Erythropoietin | Syngeneic grafts | Calcineurin | Calcineurin inhibitors | Blood transfusion | Immunosuppressive agents | Hepatitis | Allografts | Drug therapy | Genotypes | Antiviral agents | Recurrent infection | Fatigue | Proteinase inhibitors | Patients | RNA-directed RNA polymerase | Cough | Blood levels | Graft rejection | Fibrosis | Interferon | Antiviral drugs | Liver transplantation | Index Medicus | Abridged Index Medicus | Medicaments antivírics | Hepatitis C virus | Virus de l'hepatitis C | Trasplantament hepàtic | Hepatic transplantation
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2014, Volume 14, Issue 7, pp. 581 - 589
Journal Article